Published in Psychopharmacology (Berl) on May 22, 2003
Second-generation antipsychotics: discrepancies between licensed indications, evidence base and actual use. Psychopharmacology (Berl) (2003) 0.75
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ (2000) 6.67
Adjusting Europe's drug regulation to public health needs. Lancet (2001) 2.64
The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry (1994) 0.95
Off-label use of antipsychotic drugs. J Clin Psychopharmacol (2000) 0.94
Regulatory issues in Europe. J Clin Psychopharmacol (2001) 0.75
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet (2009) 14.52
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (2013) 8.20
Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet (2011) 6.11
Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ (2002) 5.27
Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol (2006) 3.30
Components of a modern mental health service: a pragmatic balance of community and hospital care: overview of systematic evidence. Br J Psychiatry (2004) 3.20
Mental health and psychosocial support in humanitarian settings: linking practice and research. Lancet (2011) 3.16
Rare diseases: what's next? Lancet (2008) 3.06
Suicide, depression, and antidepressants. BMJ (2005) 2.88
Smoking in Italy 2005-2006: effects of a comprehensive National Tobacco Regulation. Prev Med (2007) 2.61
Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations. PLoS Med (2011) 2.49
Orphan drug development is not taking off. Br J Clin Pharmacol (2009) 2.27
Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry (2006) 2.25
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res (2010) 2.21
Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry (2003) 1.94
Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry (2013) 1.80
Orphan drug development is progressing too slowly. Br J Clin Pharmacol (2006) 1.79
Disappointing biotech. BMJ (2005) 1.66
Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom (2004) 1.58
Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis (2009) 1.55
Anything new in EU pharmacovigilance? Eur J Clin Pharmacol (2011) 1.53
Balancing community-basedand hospital-based mental health care. World Psychiatry (2002) 1.52
Implementation science: understanding the translation of evidence into practice. Br J Psychiatry (2009) 1.50
Fair assessment of the merits of psychiatric research. Br J Psychiatry (2007) 1.48
Growing recognition of the importance of service user involvement in mental health service planning and evaluation. Epidemiol Psichiatr Soc (2005) 1.46
Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev (2015) 1.45
Mild depression in general practice: is the automatism of antidepressant prescribing an evidence-based approach? Acta Psychiatr Scand (2006) 1.42
Antidepressant drug prescribing among elderly subjects: a population-based study. Int J Geriatr Psychiatry (2005) 1.42
Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev (2009) 1.39
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol (2012) 1.39
Italy must invest more in science and technology. Nature (2008) 1.38
Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol (2005) 1.30
People with schizophrenia in five countries: conceptual similarities and intercultural differences in family caregiving. Schizophr Bull (2003) 1.25
The personal impact of schizophrenia in Europe. Schizophr Res (2004) 1.24
Describing, explaining or predicting mental health care costs: a guide to regression models. Methodological review. Br J Psychiatry (2003) 1.24
Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. J Affect Disord (2003) 1.22
Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol (2008) 1.20
Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Acta Psychiatr Scand (2002) 1.20
Long-term treatment of depression with antidepressants: a systematic narrative review. Can J Psychiatry (2007) 1.20
Venlafaxine for major depression. BMJ (2007) 1.20
Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ (2010) 1.18
Management of acute stress, PTSD, and bereavement: WHO recommendations. JAMA (2013) 1.16
Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. J Clin Psychiatry (2005) 1.15
Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can J Psychiatry (2007) 1.14
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One (2013) 1.13
Long-term medical conditions and major depression: strength of association for specific conditions in the general population. Can J Psychiatry (2005) 1.10
Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur J Clin Pharmacol (2004) 1.10
Influence of perceived organisational factors on job burnout: survey of community mental health staff. Br J Psychiatry (2009) 1.09
Dropping out of care: inappropriate terminations of contact with community-based psychiatric services. Br J Psychiatry (2002) 1.08
Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev (2009) 1.07
What happens to patients seen only once by psychiatric services? Findings from a follow-up study. Psychiatry Res (2007) 1.07
Demographic, clinical, social and service variables associated with higher needs for care in community psychiatric service patients. The South Verona Outcome Project 8. Soc Psychiatry Psychiatr Epidemiol (2004) 1.06
Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry (2008) 1.04
Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol (2006) 1.04
Steps, challenges and lessons in developing community mental health care. World Psychiatry (2008) 1.04
DTI studies of corpus callosum in bipolar disorder. Biochem Soc Trans (2009) 1.03
Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology (2009) 1.03
The identification of depression and the coverage of antidepressant drug prescriptions in Italian general practice. J Affect Disord (2002) 0.99
Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol (2008) 0.99
Identification and management of depression in primary care settings. A meta-review of evidence. Epidemiol Psichiatr Soc (2007) 0.99
Does community care decrease length of stay and risk of rehospitalization in new patients with schizophrenia disorders? A comparative case register study in Groningen, The Netherlands; Victoria, Australia; and South-Verona, Italy. Schizophr Bull (2002) 0.98
Are all antidepressants really the same? The case of fluoxetine: a systematic review. J Clin Psychiatry (2006) 0.98
Does meeting needs improve quality of life? Psychother Psychosom (2004) 0.98
Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev (2011) 0.98
Reconsidering the Declaration of Helsinki. Lancet (2013) 0.98
Listening to patients' needs to improve their subjective quality of life. Psychol Med (2005) 0.98
Monitoring community psychiatric services in Italy: differences between patients who leave care and those who stay in treatment. Br J Psychiatry (2002) 0.97
A census-based socio-economic status (SES) index as a tool to examine the relationship between mental health services use and deprivation. Soc Sci Med (2005) 0.96
Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol (2009) 0.95
Enlarged hypothalamic volumes in schizophrenia. Psychiatry Res (2012) 0.95
Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. Int Clin Psychopharmacol (2006) 0.95
Generic olanzapine: health authority opportunity or nightmare? Expert Rev Pharmacoecon Outcomes Res (2008) 0.94
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev (2009) 0.94
Changes and predictors of change in objective and subjective quality of life: multiwave follow-up study in community psychiatric practice. Br J Psychiatry (2005) 0.94
Frequency and adequacy of depression treatment in a Canadian population sample. Can J Psychiatry (2007) 0.94
Seven criteria for improving effectiveness trials in psychiatry. Psychol Med (2006) 0.94
Association study of dysbindin gene with clinical and outcome measures in a representative cohort of Italian schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet (2007) 0.93
Update of suicide trends in Italy from 1986 to 1996. Soc Psychiatry Psychiatr Epidemiol (2002) 0.93
Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol (2005) 0.93
Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord (2004) 0.93
Does additional care provided by a consumer self-help group improve psychiatric outcome? A study in an Italian community-based psychiatric service. Community Ment Health J (2005) 0.92
Determinants of once-only contact in a community-based psychiatric service. Soc Psychiatry Psychiatr Epidemiol (2005) 0.92
Persistence with pharmacological treatment in the specialist mental healthcare of patients with severe mental disorders. Eur J Clin Pharmacol (2012) 0.92
Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004. Pharmacoepidemiol Drug Saf (2007) 0.92
Depression in adults: drug and physical treatments. BMJ Clin Evid (2011) 0.91
The balanced care model: the case for both hospital- and community-based mental healthcare. Br J Psychiatry (2013) 0.91
Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev (2012) 0.90
Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol (2006) 0.90
Fluoxetine dose and outcome in antidepressant drug trials. Eur J Clin Pharmacol (2002) 0.90
Satisfaction with mental health services among people with schizophrenia in five European sites: results from the EPSILON Study. Schizophr Bull (2003) 0.90
If you could only choose five psychotropic medicines: updating the interagency emergency health kit. PLoS Med (2011) 0.89
Publication bias in systematic reviews. Arch Gen Psychiatry (2007) 0.89
A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med (2007) 0.89
Patterns of benzodiazepine use in a Canadian population sample. Epidemiol Psichiatr Soc (2009) 0.89